肠道微生物群与转移性肾细胞癌中舒尼替尼诱导的腹泻：一项初步研究
Gut Microbiota and Sunitinib-Induced Diarrhea in Metastatic Renal Cell Carcinoma: A Pilot Study.
作者信息
Su Zhimin, Lu Linbin, Chen Fuyu, Chen Jianhui, Chen Xiong
机构信息
Department of Oncology, 900th Hospital of PLA, Fuzong Clinical Medical College of Fujian Medical University, Fuzhou, 350024, People's Republic of China.
Department of Medical Oncology, Xiamen Branch, Zhongshan Hospital, Fudan University, Xiamen, 361015, People's Republic of China.
出版信息
Cancer Manag Res. 2021 Nov 20;13:8663-8672. doi: 10.2147/CMAR.S328451. eCollection 2021.
INTRODUCTION
Sunitinib-induced diarrhea seriously affects the prognosis of patients with metastatic renal cell carcinoma (mRCC) and reduces their quality of life. We aim to explore and find the relationship between sunitinib-induced diarrhea and gut microbiota.
METHODS
Feces were collected from 31 mRCC patients receiving sunitinib treatment. To characterize the feces gut microbiome profiles of patients, the V3-V4 region of 16S rRNA sequencing was carried out in this study.
RESULTS
Gut microbial diversity was decreased both in the severe diarrhea group and in the sunitinib-post group. The microbial composition with higher abundance of (mucus degrading bacteria) and lower abundance of and (butyrate-producing bacteria) were found in patients with diarrhea. Interestingly, the abundance of was decreased in patients receiving sunitinib with severe diarrhea.
CONCLUSION
This study reported an association between gut microbiota and sunitinib-induced diarrhea. Defects of the butyrate-producing bacteria and the increase in may be the physiological basis of sunitinib-induced diarrhea.
引言
舒尼替尼引起的腹泻严重影响转移性肾细胞癌（mRCC）患者的预后，并降低其生活质量。我们旨在探索并找出舒尼替尼引起的腹泻与肠道微生物群之间的关系。
方法
收集31例接受舒尼替尼治疗的mRCC患者的粪便。为了表征患者粪便的肠道微生物群特征，本研究进行了16S rRNA测序的V3-V4区域分析。
结果
严重腹泻组和舒尼替尼治疗后组的肠道微生物多样性均降低。腹泻患者中发现了微生物组成，其中（黏液降解菌）丰度较高，而（产丁酸菌）和丰度较低。有趣的是，接受舒尼替尼治疗且伴有严重腹泻的患者中，的丰度降低。
结论
本研究报告了肠道微生物群与舒尼替尼引起的腹泻之间的关联。产丁酸菌的缺陷和的增加可能是舒尼替尼引起腹泻的生理基础。
Zotero 插件